Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 640268306 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Two Seas Capital LP
13G/A
Amendment 2
|
9.8% |
9/28/2026
Event 9/25/2026
|
|
| Two Seas Capital LP | 9.8% | ||
| Two Seas Capital GP LLC | 9.8% | ||
| Sina Toussi | 9.8% | ||
|
Two Seas Capital LP
13G/A
Amendment 1
|
9.1% |
8/14/2026
Event 6/30/2026
|
|
| Two Seas Capital LP | 9.1% | ||
| Two Seas Capital GP LLC | 9.1% | ||
| Sina Toussi | 9.1% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
7.1% |
8/14/2026
Event 6/30/2026
|
|
| Biotechnology Value Fund L P | 3.7% | ||
| BVF I GP LLC | 3.7% | ||
| Biotechnology Value Fund II LP | 2.8% | ||
| BVF II GP LLC | 2.8% | ||
| Biotechnology Value Trading Fund OS LP | 0.5% | ||
| BVF Partners OS Ltd. | 0.5% | ||
| BVF GP Holdings LLC | 6.5% | ||
| BVF Partners L P/IL | 7.1% | ||
| BVF Inc/IL | 7.1% | ||
| Lampert Mark N | 7.1% | ||
| Vanguard Capital Management LLC 13G | 5.2% |
7/31/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G | 7.8% |
7/29/2026
Event 6/30/2026
|
|
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
9.8% |
5/15/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 5.3% | ||
| BVF I GP LLC | 5.3% | ||
| Biotechnology Value Fund II LP | 3.9% | ||
| BVF II GP LLC | 3.9% | ||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||
| BVF Partners OS Ltd. | 0.6% | ||
| BVF GP Holdings LLC | 9.1% | ||
| BVF Partners L P/IL | 9.8% | ||
| BVF Inc/IL | 9.8% | ||
| Lampert Mark N | 9.8% | ||
|
FMR LLC
13G/A
Amendment 1
|
15.0% |
5/6/2026
Event 3/31/2026
|
|
| FMR LLC | 15.0% | ||
| Abigail P. Johnson | 15.0% | ||
|
Two Seas Capital LP
13G
|
6.8% |
4/17/2026
Event 3/31/2026
|
|
| Two Seas Capital LP | 6.8% | ||
| Two Seas Capital GP LLC | 6.8% | ||
| Sina Toussi | 6.8% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
FMR LLC
13G
|
11.1% |
3/6/2026
Event 2/27/2026
|
|
| FMR LLC | 11.1% | ||
| Abigail P. Johnson | 11.1% | ||
|
Susquehanna Securities, LLC
13G/A
Amendment 1
|
4.0% |
2/13/2026
Event 12/31/2025
|
|
| G1 Execution Services, LLC | 4.0% | ||
| Susquehanna Portfolio Strategies, LLC | 4.0% | ||
| Susquehanna Securities, LLC | 4.0% | ||
| Vanguard Group Inc 13G | 5.0% |
1/30/2026
Event 12/31/2025
|
|
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
2.2% |
11/14/2025
Event 9/30/2025
|
|
| Nantahala Capital Management, LLC | 2.2% | ||
| Wilmot B. Harkey | 2.2% | ||
| Daniel Mack | 2.2% | ||
|
Susquehanna Securities, LLC
13G
|
6.3% |
11/13/2025
Event 9/30/2025
|
|
| Susquehanna Portfolio Strategies, LLC | 6.3% | ||
| Susquehanna Securities, LLC | 6.3% | ||
| Vanguard Group Inc 13G/A Amendment 14 | 4.98% |
10/31/2025
Event 9/30/2025
|
|
|
Integrated Core Strategies (US) LLC
13G/A
Amendment 1
|
3.0% |
10/28/2025
Event 9/30/2025
|
|
| Integrated Core Strategies (US) LLC | 1.8% | ||
| Millennium Management LLC | 3.0% | ||
| Millennium Group Management LLC | 3.0% | ||
| Israel A. Englander | 3.0% | ||
|
Nantahala Capital Management, LLC
13G
|
5.7% |
8/14/2025
Event 6/30/2025
|
|
| Nantahala Capital Management, LLC | 5.7% | ||
| Wilmot B. Harkey | 5.7% | ||
| Daniel Mack | 5.7% | ||
| BlackRock, Inc. 13G/A Amendment 2 | 1.6% |
7/18/2025
Event 6/30/2025
|
|
|
Biotechnology Value Fund L P
13G
|
7.4% |
7/9/2025
Event 7/1/2025
|
|
| Biotechnology Value Fund L P | 3.8% | ||
| BVF I GP LLC | 3.8% | ||
| Biotechnology Value Fund II LP | 3.0% | ||
| BVF II GP LLC | 3.0% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 6.8% | ||
| BVF Partners L P/IL | 7.4% | ||
| BVF Inc/IL | 7.4% | ||
| Lampert Mark N | 7.4% | ||
|
Integrated Core Strategies (US) LLC
13G
|
5.4% |
7/3/2025
Event 6/27/2025
|
|
| Integrated Core Strategies (US) LLC | 4.7% | ||
| Millennium Management LLC | 5.4% | ||
| Millennium Group Management LLC | 5.4% | ||
| Israel A. Englander | 5.4% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 3.35 M | $203 M |
| 2026 Q2 | 257 | 38.3 M | $2.54 B |
| 2026 Q1 | 222 | 26.9 M | $1.94 B |
| 2025 Q4 | 188 | 17.3 M | $732 M |
| 2025 Q3 | 164 | 14.4 M | $820 M |
| 2025 Q2 | 116 | 7.66 M | $198 M |
| 2023 Q1 | 1 | 33.0 | $23.00 |
| 2022 Q4 | 1 | 33.0 | $75.00 |
| 2022 Q3 | 1 | 33.0 | $106.00 |
| 2022 Q2 | 1 | 33.0 | $125.00 |
| 2022 Q1 | 1 | 33.0 | $178.00 |
| 2021 Q4 | 1 | 33.0 | $446.00 |
| 2021 Q3 | 1 | 33.0 | $593.00 |
| 2021 Q2 | 1 | 33.0 | $566.00 |
| 2021 Q1 | 1 | 33.0 | $660.00 |
| 2020 Q4 | 1 | 33.0 | $561.00 |
| 2020 Q3 | 1 | 33.0 | $547.00 |
| 2020 Q2 | 1 | 33.0 | $764.00 |
| 2020 Q1 | 1 | 33.0 | $589.00 |
| 2019 Q4 | 1 | 33.0 | $712.00 |
| 2019 Q3 | 1 | 17.0 | $310.00 |
| 2019 Q1 | 1 | 17.0 | $571.00 |
| 2018 Q4 | 1 | 17.0 | $559.00 |
| 2018 Q3 | 1 | 17.0 | $1.04 k |
| 2018 Q2 | 1 | 17.0 | $830.00 |
| 2018 Q1 | 1 | 17.0 | $1.81 k |